Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

EU OK To Tecentriq-Avastin Combo In NSCLC Includes EGFR-Mutant, ALK-Positive Patients

Mar 11 2019

• By Sten Stovall

Cancer cells — EU Nod For Tecentriq with Avastin is based on IMpower150 study • Source: Shutterstock

Related Content

Roche's IMpower150 Gets AACR Applause But Merck's KEYNOTE-189 Big Winner

Apr 17 2018

Roche's Tecentriq Positive But Not Perfect In IMpower130 First-line Lung Cancer Study

Oct 23 2018

Roche's Tecentriq Becomes Second In PD-1/L1 Family To Gain First-Line Lung Cancer Approval

Dec 07 2018

Cancer Drug Combination Pricing: Genentech Offers Model For Tecentriq, Avastin

Jan 23 2019

Related Companies

Roche Holding AG

Merck & Co., Inc.

AstraZeneca PLC

Genentech, Inc.

Additional Topics

ImmunoOncology Approvals Reimbursement Cancer BioPharmaceutical

More from Immuno-oncology

More from Anticancer

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window